Autologous Bone Marrow Mesenchymal Stem Cells in Chronic Achilles Tendon Ruptures. Prospective Case Series.

Autologous Bone Marrow Mesenchymal Stem Cells in Chronic Achilles Tendon Ruptures. Prospective Case Series.

Rafael Arriaza-Loureda, MD, PhD, SPAIN Robert Soler-Rich, MD, PhD, SPAIN Gil Rodas, MD, SPAIN Lluis Orozco, MD, SPAIN

Instituto de Terapia Regenerativa Tisular, Barcelona, SPAIN


2025 Congress   ePoster Presentation   2025 Congress   Not yet rated

 

Treatment / Technique

Anatomic Structure

Diagnosis / Condition

Diagnosis Method

MRI

Sports Medicine


Summary: A series of patients with chronic Achilles tendon rupture treated non-surgically, via percutaneous injection of ex vivo culture-expanded autologous bone marrow mesenchymal stem cells is presented. Results show that it is technically and clinically feasible, as well as being safe and able to to regenerate tendon tissue in such cases. All patients reached excellent result without complications


BACKGROUND. Management of chronic Achilles tendon rupture (ATR) involves demanding surgery, use of grafts and prolonged rehabilitation.
STUDY DESIGN: Prospective case series
METHODS. Seven patients with image-confirmed symptomatic chronic ATR were treated non-surgically, with percutaneous injection of intratendinous culture-expanded aBM-MSCs [20(±2)x10 6 ] and immediate post-injection mobilization. The patients followed standard rehabilitation. We assessed pre- and post-treatment changes in tendon structure using magnetic resonance imaging, pain on the visual analog scale (VAS), Victorian Institute Sport Assessment (VISA-A) scores, and clinical complications at 12 and 24 months post-treatment.
RESULTS. The injection of aBM-MSC treatment was safe and well tolerated. Achilles tendon tissue regenerated in all patients by the last visit, and all recovered tendon function. aBM-MSCs reduced internal tendon swelling and fluid, as well as regenerated tissue and collagen fibers. Patients reported significantly reduced pain [median scores: VAS (-8.5), VAS sport (-9.7), and improved VISA-A (86.5)]. All patients returned to their pre-injury daily activities immediately and to recreational sports activities by four months post-injection.
CONCLUSION. The intratendinous injection of culture-expanded aBM-MSCs is feasible and safe and should be considered a promising option in the personalized treatment of chronic ATR. Randomized clinical trials are needed to substantiate these results